Association between time to adjuvant chemotherapy and survival in ovarian cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

ABSTRACT:

Introduction

Delayed adjuvant chemotherapy (AC) worsens survival in advanced ovarian cancer (OC), but data on its impact after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is limited. We aimed to assess if delayed AC negatively affects survival in OC patients treated with CRS/HIPEC.

Methods

We conducted a retrospective analysis of a single-center prospective database including FIGO stage III-IV epithelial OC patients who underwent initial CRS/HIPEC (upfront or interval) followed by AC. Patients were grouped into delayed AC (≥60 days) and no delay (<60 days). Patient characteristics were compared. Logistic regression identified risk factors for delay. Kaplan-Meier method and stratified Wilcoxon test were used for survival analysis.

Result

SUBMITTER: Iugai S 

PROVIDER: S-EPMC11908597 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature